NRAS and KRAS mutations share phenotypic traits, such as promoting tumorigenicity, but certain NRAS variants like Q61K can enhance tumor proliferation, while others like G12D might reduce proliferation and increase apoptosis. Here, KRAS is linked to neoplasm.